Related Experiment Videos
Sudden death and staged therapy for hemodynamic stabilization in patients enrolled in a heart transplantation program
Insights
Staged therapy for advanced heart failure reduced sudden cardiac death compared to conventional treatment. This approach improved survival outcomes in patients with severe heart conditions.
Area of Science:
- Cardiology
- Clinical Medicine
Background:
- Advanced heart failure presents significant therapeutic challenges.
- Conventional treatments often fail to adequately address severe heart failure, leading to poor outcomes.
Purpose of the Study:
- To evaluate the effectiveness of a staged therapeutic approach for advanced heart failure.
- To compare therapeutic endpoints between conventional and staged therapy strategies.
Main Methods:
- Prospective follow-up of 236 advanced heart failure patients.
- Conventional therapy group (n=137): digoxin, furosemide, low-dose ACE inhibitors, with transplantation for refractory cases.
- Staged therapy group (n=99): maximal ACE inhibition, PGE1 for hemodynamic stabilization, or dobutamine bridging to transplantation.
Main Results:
- Conventional therapy: 28% mortality (39/137), with 13% sudden deaths and 87% pump failure deaths.
- Staged therapy: 25% mortality (25/99), with 52% sudden deaths and 48% pump failure deaths.
- Staged therapy showed a higher proportion of sudden deaths but a lower overall mortality rate.
Conclusions:
- Staged therapy for advanced heart failure may alter the pattern of death, with a higher incidence of sudden death but potentially improved overall survival.
- Further research is needed to optimize staged protocols and understand the mechanisms behind the shift in mortality patterns.
Abstract:
To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease/dilated cardiomyopathy in 61/175 patients, left ventricular ejection fraction 14% +/- 5%, New York Heart Association Class II/III/IV in 102/79/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirty-seven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninety-nine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PGE1 for pre- and afterload reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 +/- 9 months; patients who underwent staged therapy for 9 +/- 5 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died: 13 (52%) deaths occurred suddenly, and 12 (48%) deaths occurred due to progressive pump failure.(ABSTRACT TRUNCATED AT 250 WORDS)